NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1019 coverStrategies for Engineered Negligible Senescence: Why Genuine Control of Aging May Be Foreseeable Volume 1019 published June 2004
Ann. N.Y. Acad. Sci. 1019: 64–69 (2004). doi: 10.1196/annals.1297.014
Copyright © 2004 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by UKRAINTSEVA, S. V.
Articles by YASHIN, A. I.
Search for Related Content
PubMed
PubMed Citation
Articles by UKRAINTSEVA, S. V.
Articles by YASHIN, A. I.
Antiaging Treatments Have Been Legally Prescribed for Approximately Thirty Years

SVETLANA V. UKRAINTSEVAa,c, KONSTANTIN G. ARBEEVa,c, ANATOLY I. MICHALSKYb AND ANATOLY I. YASHINa,c

aMax Planck Institute for Demographic Research, 18057 Rostock, Germany
bInstitute of Management Problems, Moscow, Russia
cDuke University, Center for Demographic Studies, Durham, North Carolina, USA

Address for correspondence: Svetlana V. Ukraintseva, Ph.D., Duke University Center for Demographic Studies, 2117 Campus Drive, Box 90408, Durham, NC 27708-0408. Voice: 919-682-9759, ext. 224. ukraintseva{at}cds.duke.edu
Ann. N.Y. Acad. Sci. 1019: 64-69 (2004).

There is an interesting divergence between the achievements of geriatrics and gerontology. On the one hand, during the last 30 years physicians in many developed countries have successfully prescribed several medicines to cure various symptoms of senescence. On the other hand, the influence of such medicines on human life span practically has not been studied. The most common of the relevant medicines are nootropic piracetam, gamma-aminobutyric acid (GABA), selegiline, Ginkgo biloba, pentoxifylline, cerebrolysin, solcoseryl, ergoloid, vinpocetin, sertraline, and estrogens, among others. Available data from human clinical practices and experimental animal studies indicate that treatments with these drugs improve learning, memory, brain metabolism, and capacity. Some of these drugs increase tolerance to various stresses such as oxygen deficit and exercise, stimulate the regeneration of neurons in the old brain, and speed up the performance of mental and physical tasks. This means that modern medicine already has "antiaging" treatments at its disposal. However, the influence of such treatments on the mean and maximal life span of humans, and on the age trajectory of a human survival curve has been poorly studied. The increase in human life expectancy at birth in the second half of the last century was mostly caused by the better survival at the old and oldest old rather than at the young ages. In parallel, the consumption of brain protective and regenerative drugs has been expanding in the elderly population. We provide evidence in support of the idea that the consumption of medicines exerting antiaging properties may contribute to the increase in human longevity.

Key Words: antiaging drugs • longevity • cognitive functioning




This article has been cited by other articles:


Home page
StrokeHome page
S. Ukraintseva, F. Sloan, K. Arbeev, and A. Yashin
Increasing Rates of Dementia at Time of Declining Mortality From Stroke
Stroke, May 1, 2006; 37(5): 1155 - 1159.
[Abstract] [Full Text] [PDF]



footerLeft footerRight